MOREPENLAB · Morepen Laboratories Ltd · Biotechnology & Drugs
MOREPENLAB · Morepen Laboratories Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
35.6% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹570 Cr
Revenue YoY
PAT YoY
+424.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
5.2
P/S (TTM)
3.3
Sector P/E
36.3
Dividend yield
+0.2%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| MOREPENLAB (this stock) | 23.1 | 5.2 | +7.2% | +11.3% | 0.17 | +0.2% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 1q
MF
0.05%
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| MOREPENLAB | 2026-11-04 | 3667667 | 1 | STRONG | BULK |
| MOREPENLAB | 2026-09-16 | 2528438 | 1 | MEDIUM | BULK |
| MOREPENLAB | 2026-08-31 | 3176302 | 1 | WEAK | BULK |
| MOREPENLAB | 2026-08-20 | 5940294 | 2 | WEAK | BULK |
| MOREPENLAB | 2026-08-17 | 3672287 | 1 | MEDIUM | BULK |
| MOREPENLAB | 2026-08-14 | 2963079 | 1 | STRONG | BULK |
| MOREPENLAB | 2026-08-13 | 2827296 | 1 | MEDIUM | BULK |
| MOREPENLAB | 2026-08-05 | 16636317 | 4 | WEAK | BULK |
| MOREPENLAB | 2026-06-30 | 2834192 | 1 | STRONG | BULK |
News timeline
- lowthehindubusinessline.com· 15 Oct 2026, 07:32 amBuzzing stocks: Eyes on these 14 including LIC, Reliance, IDBI Bank, NLC India, Dr Reddy’s Lab, Morepen Lab, Aeroflex
- unknownthehindubusinessline.com· 28 Sept 2026, 03:24 pmMorepen files first US drug application, eyes generic diabetes market
- mediumcorporate actionbusiness-standard.com· 07 Sept 2026, 12:50 pmMorepen Labs Share Price: Morepen Labs rises 7% to 52-week high; what moved this multibagger stock?
Concalls & investor presentations
AI-generatedKey takeaway: Morepen Laboratories Limited's Q2 and H1 FY27 investor presentation highlights strong financial performance, with two consecutive quarters of record revenue and earnings. Revenue for Q2 FY27 reached Rs. 755 crore, up 273% year-over-year, while EBITDA was Rs. 132 crore, reflecting a 897 basis point increase in EBITDA margin. For H1 FY27, revenue totaled Rs. 1,330 crore, a 57% increase from the prior year, with EBITDA at Rs. 220 crore and a 16.50% margin. PAT grew by 243% year-over-year. The company emphasized its CDMO segment's scale-up, with CDMO revenue contributing over 52% of API and CDMO combined revenue. API revenue saw a 25% share from new molecules, and exports grew by 122% year-over-year, now representing 50% of total sales. The presentation also noted improvements in financial metrics, including ROCE at 18.8% and a debt-to-equity ratio of 0.23. Strategic focus areas include expanding global programs, enhancing innovation through new technologies, and scaling medical devices under a chronic-care franchise. The company highlighted its platform's diversification, compliance, and scalability for long-term growth.
The presentation emphasizes strong revenue and earnings growth, significant improvements in financial metrics, and strategic advancements in CDMO and API segments, reflecting a positive outlook.
Sourced from an exchange-filed presentation, dated 27 Oct 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Morepen Laboratories Limited's investor presentation for Q1 FY27 highlighted significant financial achievements, including the highest-ever quarterly revenue of Rs. 825 crore and a 3x year-over-year increase in EBITDA, reaching Rs. 87.72 crore. The presentation emphasized the commercial validation of the Morepen 2.0 strategy, with a focus on operational execution leading to a 15%+ EBITDA margin. The company reported a 111% increase in export revenue and a 394% rise in profit after tax (PAT) to Rs. 56.35 crore. Management noted a transition from commodity APIs to innovation-led manufacturing, aiming for predictable earnings through long-duration customer programs. The presentation also outlined plans for capacity expansion and a commitment to sustainable operations, supporting long-term growth and global partnerships.
The presentation emphasized strong financial performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 04 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Morepen Laboratories Limited's investor presentation for Q4 and FY26 highlighted the company's financial performance, reporting a 22% year-over-year revenue increase to Rs. 472 crore in Q4 FY26. The API segment grew by 17%, while the medical devices segment saw a 31% increase. For FY26, total revenue reached Rs. 597 crore, marking an 8% growth. Management described FY26 as a transition year, emphasizing strengthened long-duration manufacturing partnerships and capacity expansions. The presentation noted the company's established leadership in key APIs, with a strong export presence in over 90 countries and a focus on long-term supply contracts. Additionally, the company achieved a fourth consecutive USFDA inspection with no observations. Management indicated that operational momentum improved towards the end of FY26, supported by strategic investments and a focus on recurring revenues.
The presentation emphasized growth and strategic advancements in the company's operations.
Sourced from an exchange-filed presentation, dated 27 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Morepen Laboratories Limited's investor presentation for Q3 FY26 detailed the company's financial performance for the quarter and the nine months ending December 31, 2025. The presentation highlighted that the gross revenue for Q3 FY26 was reported at Rs. 462 crores, reflecting a 23% increase from the previous quarter. The company noted that its pharma business contributed 62% to total revenue, while medical devices accounted for 38%. The revenue from the pharma segment showed a slight decline, with total pharma revenue at Rs. 285 crores for Q3 FY26. In the medical devices segment, total revenue reached Rs. 177 crores, marking an 18% increase. The presentation also provided insights into the geographical distribution of revenue, with India being the largest market. Management emphasized the importance of their product offerings in both segments and outlined their growth strategy.
The presentation provided a balanced overview of financial performance without strong emphasis on growth or challenges.
Sourced from an exchange-filed presentation, dated 10 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedMorepen Laboratories Limited's FY2025-26 annual report highlights strategic initiatives focused on expanding manufacturing capacity, innovation in chemistry, digital health, and long-term global partnerships. The company emphasizes strengthening its core healthcare businesses, including APIs, Medical Devices, and Formulations, while transitioning from a product-led API business to an integrated, innovation-driven manufacturing and healthcare platform. The report also outlines efforts in corporate social responsibility, governance, and sustainability, alongside challenges such as margin pressures and regulatory scrutiny.
- Strategic focus on expanding manufacturing capacity and innovation-led chemistry.
- Transition from a product-led API business to an integrated healthcare platform.
- Commitment to corporate social responsibility and sustainability initiatives.
- Strengthening global partnerships and digital health initiatives.
Key takeaway: Morepen is transitioning towards an integrated, innovation-driven healthcare platform while addressing challenges such as margin pressures and regulatory scrutiny.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (4 items); Default / Covenant Breach (2 items); Investigation or enforcement mention (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceOlder (3+ years ago)
The auditor's report mentions that the company's financial statements may not be presented fairly due to the impact of the NCLT's 2018 order on the Scheme of Arrangement, which affects the valuation and disclosure of shares issued to fixed deposit holders.
Regulatory Action
4 occurrencesRecent (last 12 months)
SEBI had restrained the company from accessing the securities market and dealing in securities for one year in 2019, but this order was set aside by SAT in 2021. SEBI appealed to the Supreme Court, and the matter is pending adjudication.
Earlier (1-3 years ago)
SEBI filed an application on 20 July 2021 before the Supreme Court against the SAT's 15 April 2021 order, which had set aside SEBI's 24 September 2019 order prohibiting the company from accessing the securities market for one year. The Supreme Court admitted SEBI's appeal on 22 April 2025, and the matter is pending adjudication.
The company has pending regulatory actions including 14 matters under adjudication and a SEBI application pending before the Supreme Court regarding a securities market access prohibition order.
Older (3+ years ago)
The company is involved in a legal matter before the NCLT, Chandigarh, challenging the requirement to appoint government nominee directors, with the Central Government filing a contempt petition for non-compliance of a CLB order dated 1.7.2005. The matter is under adjudication.
Default / Covenant Breach
2 occurrencesRecent (last 12 months)
The company had advance income tax dues with applicable interest outstanding as of 31 March 2026 for more than six months from their due date. These dues were subsequently paid before the financial statements were signed.
Older (3+ years ago)
The company has not made any default in the repayment of loans or interest to Banks/FIs.
Investigation or enforcement mention
1 occurrenceRecent (last 12 months)
The excerpt mentions suspected fraud or irregularity and failure of internal control systems of a material nature, which has been reported to the Board.
Routine disclosures
Contingent Liability
4 occurrencesRecent (last 12 months)
The company has a contingent liability of ₹31736.62 Lakhs towards GST demand raised by Commissioner, Central GST & Central Excise Commissionerate, Shimla.
Earlier (1-3 years ago)
The company has contingent liabilities including claims not acknowledged as debts, guarantees, and other monetary liabilities for which the company is contingently liable.
The company has a contingent liability related to a trademark 'Burnol' pledged as collateral security to Poysha Power Generation (P) Ltd. against an inter-corporate deposit. A legal case regarding this trademark is pending adjudication.
Older (3+ years ago)
The company has 9,735,201 optionally convertible preference shares that became due for redemption in 2014-15 but could not be redeemed due to unavailability of surplus.
Related-Party Transaction
4 occurrencesRecent (last 12 months)
The company extended the time for hiving off its Medical Devices Business into Morepen Medipath Limited, a subsidiary, as a material related party transaction.
Earlier (1-3 years ago)
The company has approved a material related party transaction involving the hive-off of its Medical Devices Business to Morepen Medipath Limited, a subsidiary, on or before 30 September 2025, with the extension of time to complete the transaction till the Annual General Meeting for 2025-26.
The company has transactions with relatives of key management personnel, including Mr. Anubhav Suri and others, and entities where KMPs or their relatives have significant influence, such as Edit 25 Lifestyle Private Limited and Blueheaven Marketing Pvt. Ltd.
Older (3+ years ago)
The company has transactions with relatives of key management personnel, including Mr. Varun Suri, Mr. Anubhav Suri, Mr. Kushal Suri, and others, as well as entities controlled by them such as Brook Investments & Financial Services Pvt. Ltd., Concept Credits & Consultants Pvt. Ltd., and others.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
9.26% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).